Autopsy report · NCT01266018
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Cause of deathSlow enrollment, also futility
“Lack of efficacy in Cohort 2; slow enrollment in Cohort 1”
Life of this trial
- Ran for about 3 years before it stopped.
- 22 participants enrolled.
- Results were posted on the registry 3 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Ludwig Institute for Cancer Research
- Sponsor type
- University, hospital or other
- Conditions
- Small Cell Lung Cancer
- Interventions
- ADI-PEG 20 (Arginine deiminase pegylated)
- Participants
- 22
- Sites
- 8
- Countries
- Belgium, Germany, Taiwan, United Kingdom, United States
Trials that died the same way
- Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
“Lack of efficacy and enrollment challenges” - Use of 3M Cavilon Advanced Skin Protectant in the Management of Damaged Skin Around an Ostomy, Drain or Fistula
“Slow enrollment of patients” - Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
“Slow enrollment with limited population for study parameters.” - A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
“Slow participant enrollment” - Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
“Slower than anticipated enrollment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.